Teva Pharmaceutical Industries Limited (NYSE:TEVA) CAO Amir Weiss Sells 15,500 Shares of Stock

Teva Pharmaceutical Industries Limited (NYSE:TEVA - Get Free Report) CAO Amir Weiss sold 15,500 shares of the firm's stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $16.80, for a total transaction of $260,400.00. Following the completion of the transaction, the chief accounting officer now directly owns 17,814 shares in the company, valued at $299,275.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

Teva Pharmaceutical Industries Stock Down 0.1 %

NYSE:TEVA traded down $0.02 during midday trading on Friday, reaching $16.29. The company had a trading volume of 7,789,982 shares, compared to its average volume of 11,056,235. Teva Pharmaceutical Industries Limited has a 12-month low of $7.09 and a 12-month high of $17.13. The firm has a market capitalization of $18.26 billion, a price-to-earnings ratio of -39.72, a PEG ratio of 2.00 and a beta of 1.04. The company has a current ratio of 0.89, a quick ratio of 0.61 and a debt-to-equity ratio of 2.20. The stock's fifty day simple moving average is $14.06 and its 200-day simple moving average is $12.04.

Analysts Set New Price Targets

Several analysts have issued reports on TEVA shares. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from an "underweight" rating to a "neutral" rating and set a $14.00 target price for the company in a report on Friday, March 8th. The Goldman Sachs Group upped their price target on Teva Pharmaceutical Industries from $10.00 to $11.00 and gave the company a "neutral" rating in a research note on Monday, February 5th. Barclays raised their price objective on Teva Pharmaceutical Industries from $17.00 to $20.00 and gave the stock an "overweight" rating in a research report on Thursday, May 9th. StockNews.com cut shares of Teva Pharmaceutical Industries from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 10th. Finally, Jefferies Financial Group raised shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating and boosted their price target for the company from $10.00 to $14.00 in a research note on Tuesday, January 23rd. Three investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Teva Pharmaceutical Industries presently has a consensus rating of "Moderate Buy" and an average price target of $14.22.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

A number of institutional investors and hedge funds have recently made changes to their positions in TEVA. Assenagon Asset Management S.A. increased its position in shares of Teva Pharmaceutical Industries by 705.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 579,562 shares of the company's stock valued at $6,051,000 after purchasing an additional 507,568 shares during the last quarter. Los Angeles Capital Management LLC purchased a new stake in Teva Pharmaceutical Industries during the 3rd quarter worth about $3,000,000. SG Americas Securities LLC boosted its position in shares of Teva Pharmaceutical Industries by 31.7% during the 4th quarter. SG Americas Securities LLC now owns 544,878 shares of the company's stock worth $5,689,000 after acquiring an additional 131,043 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Teva Pharmaceutical Industries by 42.2% in the 3rd quarter. Wellington Management Group LLP now owns 344,587 shares of the company's stock valued at $3,515,000 after acquiring an additional 102,261 shares during the last quarter. Finally, Gateway Investment Advisers LLC raised its position in shares of Teva Pharmaceutical Industries by 28.6% during the 4th quarter. Gateway Investment Advisers LLC now owns 41,882 shares of the company's stock worth $437,000 after acquiring an additional 9,312 shares in the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.